| Literature DB >> 32956719 |
Christian G Figueroa-Espada1, Samuel Hofbauer2, Michael J Mitchell3, Rachel S Riley4.
Abstract
A major challenge to treating diseases during pregnancy is that small molecule therapeutics are transported through the placenta and incur toxicities to the developing fetus. The placenta is responsible for providing nutrients, removing waste, and protecting the fetus from toxic substances. Thus, the placenta acts as a biological barrier between the mother and fetus that can be exploited for drug delivery. Nanoparticle technologies provide the opportunity for safe drug delivery during pregnancy by controlling how therapeutics interact with the placenta. In this Review, we present nanoparticle drug delivery technologies specifically designed to exploit the placenta as a biological barrier to treat maternal, placental, or fetal diseases exclusively, while minimizing off-target toxicities. Further, we discuss opportunities, challenges, and future directions for implementing drug delivery technologies during pregnancy.Entities:
Keywords: Active targeting; Drug delivery technologies; Nanoparticle; Placenta; Pre-eclampsia; Pregnancy
Year: 2020 PMID: 32956719 DOI: 10.1016/j.addr.2020.09.006
Source DB: PubMed Journal: Adv Drug Deliv Rev ISSN: 0169-409X Impact factor: 15.470